An ongoing phase II clinical trial is investigating the efficacy of atezolizumab, a humanized PD-L1 monoclonal antibody, in combination with small molecule inhibitors or cytotoxic agents in the most aggressive forms of thyroid cancer (NCT03181100). This evidence concerns the gene CD274 and thyroid cancer.